DiaSys Corporation Announces the Introduction of Unique New Urine Centrifuge Tube.

Business Editors/Health/Medical Writers

WATERBURY, Conn.--(BUSINESS WIRE)--April 23, 2004

DiaSys Corporation (AMEX:DYX), a global healthcare products company, today announced the introduction of a unique urine centrifuge tube to the worldwide marketplace. The new UriPrep tube, patent pending, is designed to provide urine sediment volume standardization as recommended by the US National Committee for Clinical Laboratory Standards (NCCLS), without the use of expensive specialized pipettes.

The UriPrep tube incorporates an insert, which is designed to trap 1mL of fluid in the bottom of the tube. This is done by simply pouring-off or decanting the additional fluid volume in the centrifuge tube, saving time and increasing productivity.

Gregory Witchel, DiaSys's CEO said: "The addition of consumable products to our workstations has been a stated goal of the company. We have already sold through our initial product run of half a million units and we are receiving additional orders from both new and existing accounts. These disposable products will provide a consistent stream of aftermarket revenues to the company."

Richard Sledziona, DiaSys' Executive Vice President said: "The market potential for the UriPrep tube is enormous. Urinalysis is one of the most common tests performed in by laboratories throughout the world. By eliminating the expenses associated with purchasing and storing pipettes, and for each examination performed saving the time to manually insert individual pipettes, we feel that the UriPrep tube will gain immediate acceptance within the clinical laboratory market worldwide."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.